EMA approves marketing authorization application for Lumoxiti®
Category: #health  By Mateen Dalal  Date: 2020-01-03
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

EMA approves marketing authorization application for Lumoxiti®

Innate Pharma SA, a commercial-stage oncology-focused biotech firm, has successfully attain Marketing Authorization Application (MMA) approval for Lumoxiti from the European Medicines Agency (EMA). For the record, Lumoxiti is a first-in-class drug directed for adult patients who are suffering from refractory or relapsed hairy cell leukemia (HCL) and have received a minimum two preceding systemic therapies, including treatment with a purine nucleoside analog. 

Speaking on the approval, Pierre Dodion, MD, Executive VP & CMO, Innate Pharma, said that the drug, following its authorization by the EMA, would become first treatment available in Europe for relapsed or refractory HCL patients in over twenty years, potentially transforming the standard of care for these patients.

Dodion assured that their firm is dedicated towards addressing the unmet need for treating this rare type of cancer that could result in fatal conditions and would bring this drug to patent in Europe as soon as possible.

As per reports, the EMA filing was based on the final study of the Phase III trial of Lumoxiti, demonstrated at ASH 2019. According to the data, around 36 percent (29/80) of the relapsed or refractory HCL patients attained durable complete response (specified as a CR) with a hematological remission retained for at least 180 days.

The ORR (objective response rate) was at 75%, whereas 81% of patients with CR underwent elimination of minimal residual disease as reflected by MRD-negative status. Additionally, there was a 61% possibility that patients who attained a CR would retain it after five years.

Reportedly, the EMA filing acceptance for Lumoxiti follows the U.S. FDA (Food and Drug Administration) approval in Sept. 2018.

About Innate Pharma S.A.

It is an oncology-focused biotech organization dedicated to improving clinical and treatment results for patients through therapeutic antibodies that utilize the immune system to fight against cancer.
 

Souce Creidit – https://www.innate-pharma.com/en/news-events/press-releases/european-medicines-agency-accepts-regulatory-submission-lumoxiti-relapsed-or-refractory-hairy-cell-leukemia

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Facebook to allow staff to permanently work from home post the pandemic

Facebook to allow staff to permanently work from home post the pandemic

By Mateen Dalal

Social media giant Facebook Inc. is reportedly planning to allow staff to continue working from home even after the Coronavirus pandemic ends. Eligible staff will be able to apply for permanent work from home, although subject to their relevant manag...

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

Lo! Foods bags USD 1 million in pre-series A funding, eyes expansion

By Mateen Dalal

Lo! Foods, a Bengaluru-based consumer goods startup has reportedly secured USD 1 million during its pre-series A funding round, which was led by Chona Family Office, the former promoters of the renowned Hamvor Ice Cream. Other investors that partici...

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

U.S. DOJ to intensify review of American Airlines-JetBlue partnership

By Mateen Dalal

American Airlines and JetBlue had announced their partnership in July last year. According to the Justice Department, the deal may cause inflated fares at major traffic hubs. The United States Department of Justice (DOJ) has reportedly stepped ...